Vir Biotechnology, Inc. (VIR): restructuring charge — Vir Bio Q2 net loss narrows to $138M; initiates restructuring cutting 25% of workforce

Vir Biotechnology, Inc.

2024-Q2 EPS reported -$1.50 revenue$59,451,000

Net loss of $138.4M ($1.02/sh) vs $194.8M ($1.45/sh) in Q2 2023; cash and investments $1.43B, down $78M in quarter.
Strategic restructuring reduces workforce by ~140 employees (25%); phases out flu, COVID-19, and T-cell viral vector programs.
Expects $11–13M in restructuring charges, ~$50M annual workforce cost savings from 2025, and ~$50M program savings through 2025.
Lowers full-year 2024 GAAP operating expense guidance to $580–610M, excluding Sanofi transaction impact.
Signed exclusive worldwide license with Sanofi for clinical-stage T-cell engagers; CMO Mark Eisner appointed June 2024.

item 2.02 item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Vir Biotechnology, Inc. announced a restructuring with charges of $11 million to $13 million affecting the Company's overall operations, including phasing out programs in influenza, COVID-19, and T cell-based viral vector platform (approximately 25% of the Company’s workforce, or approximately 140 employees).

Type: restructuring
Charge: $11 million to $13 million
Affected area: the Company's overall operations, including phasing out programs in influenza, COVID-19, and T cell-based viral vector platform
Headcount: approximately 25% of the Company’s workforce, or approximately 140 employees

Exact text from the filing

believes is appropriate to support its streamlined portfolio and strategic priorities. As a result of these changes, the Company expects to incur restructuring charges between $11 million to $13 million, primarily related to employee severance cash expenditures. The Company anticipates recognizing these expenses through the fourth quarter of 2024, resulting in

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-034143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.